LSE - Delayed Quote EUR

HAEMATO AG (0VZ7.L)

Compare
15.00 -13.00 (-46.43%)
At close: April 10 at 12:44 PM GMT+1
Loading Chart for 0VZ7.L
DELL
  • Previous Close 28.00
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 28.00
  • Volume 0
  • Avg. Volume 171
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.29
  • PE Ratio (TTM) 0.11
  • EPS (TTM) 1.35
  • Earnings Date Nov 14, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO brand, and cosmetics under the brand M1 SELECT, as well as supplies third party-products. It serves clinics, pharmacies, wholesalers, and medical test centers. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany.

www.haemato.ag

76

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: 0VZ7.L

View More

Performance Overview: 0VZ7.L

Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

0VZ7.L
0.00%
MSCI WORLD
18.83%

1-Year Return

0VZ7.L
40.00%
MSCI WORLD
20.47%

3-Year Return

0VZ7.L
40.00%
MSCI WORLD
20.47%

5-Year Return

0VZ7.L
40.00%
MSCI WORLD
20.47%

Compare To: 0VZ7.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0VZ7.L

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.68%

  • Return on Assets (ttm)

    3.22%

  • Return on Equity (ttm)

    6.52%

  • Revenue (ttm)

    260.81M

  • Net Income Avi to Common (ttm)

    9.61M

  • Diluted EPS (ttm)

    1.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.94M

  • Total Debt/Equity (mrq)

    2.07%

  • Levered Free Cash Flow (ttm)

    4.64M

Research Analysis: 0VZ7.L

View More

Company Insights: 0VZ7.L

Research Reports: 0VZ7.L

View More